News
Novo shares down on Eli Lilly’s positive obesity pill data
Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...
Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...
The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk is set to benefit from a $150B market by 2030, with strong earnings potential and a favorable 14x forward P/E.
By Sukriti Gupta and Medha Singh (Reuters) -European shares fell on Tuesday, dragged down by heavyweight Novo Nordisk, while ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback